Literature DB >> 25695345

Fast-tracking novel drugs in pediatric oncology.

Vivek Subbiah1.   

Abstract

Year:  2015        PMID： 25695345      PMCID： PMC4615060          DOI： 10.1080/15384101.2015.1018049

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  Little patients, losing patience: pediatric cancer drug development.

Authors:  Jessica Boklan
Journal:  Mol Cancer Ther       Date:  2006-08       Impact factor: 6.261

Review 2.  Challenging issues in pediatric oncology.

Authors:  Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo
Journal:  Nat Rev Clin Oncol       Date:  2011-06-28       Impact factor: 66.675

3.  A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.

Authors:  Xavier Paoletti; Birgit Geoerger; François Doz; André Baruchel; François Lokiec; Christophe Le Tourneau
Journal:  Eur J Cancer       Date:  2013-03-27       Impact factor: 9.162

Review 4.  Remaining challenges in childhood cancer and newer targeted therapeutics.

Authors:  Malcolm A Smith; Gregory H Reaman
Journal:  Pediatr Clin North Am       Date:  2014-10-18       Impact factor: 3.278

Review 5.  Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.

Authors:  Vivek Subbiah
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

6.  Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience.

Authors:  Eugenie S Kleinerman; Razelle Kurzrock; Vivek Subbiah; Fernando F Corrales-Medina; Cynthia Herzog; Kenneth Hess; Daniela Egas-Bejar; David S Hong; Gerald Falchook; Pete Anderson; Cesar Nunez; Winston W Huh; Aung Naing; Apostolia M Tsimberidou; Jennifer Wheler; Sarina Piha Paul; Filip Janku
Journal:  Oncoscience       Date:  2014-07-27

7.  Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.

Authors:  Daniela Egas-Bejar; Pete M Anderson; Rishi Agarwal; Fernando Corrales-Medina; Eswaran Devarajan; Winston W Huh; Robert E Brown; Vivek Subbiah
Journal:  Oncoscience       Date:  2014-03-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.